ArticleInternational journal of nanomedicine2025
Primed Extracellular Vesicles as a Nanotherapeutic Strategy to Enhance Granulosa Cell Function in a Model of Premature Ovarian Insufficiency and Hormonal Decline.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Lysine-specific demethylase 3A (KDM3A) protects against ovarian dysfunction in premature ovarian insufficiency by transcriptional activation of ATP-binding cassette sub-family A member 7 (ABCA7)-mediated mitochondrial homeostasis.Molecular biomedicine · 2026Article
- Primed Avian Mesenchymal Stem Cell-Derived Small Extracellular Vesicles Restore Granulosa Cell Homeostasis in a CTX-Induced POI-like Dysfunction Model Under Human Menopausal Gonadotropin Stimulation.International journal of molecular sciences · 2026Article
- Exosomes in oncofertility: emerging roles in chemotherapy-induced reproductive damage and fertility preservation.Reproduction & fertility · 2026Review
- Recombinant humanized type III collagen improves ovarian function via ITGA2-mediated mitochondrial function restoration in granulosa cells and extracellular matrix remodeling.Regenerative biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Premature ovarian insufficiency (POI) is characterized by granulosa cell (GC) dysfunction, reduced steroidogenesis, and hypoestrogenism, often secondary to chemotherapy. Despite advancements in regenerative medicine, cell-free nanotherapies remain underexplored for POI treatment. Purpose: This study investigates the therapeutic efficacy of primed avian mesenchymal stem cell-derived small extracellular vesicles (primed AMSC-sEVs) in a cyclophosphamide (CTX)-induced GC injury model, mimicking POI-associated hormonal dysfunction. Methods: Primed AMSC-sEVs were characterized in terms of particle size, concentration, and zeta potential using the Exoid TRPS and electrophoretic mobility platforms. Functional comparisons between primed and naïve AMSC-sEVs were conducted in human granulosa cells (hGCs), evaluating cell viability, apoptosis, steroidogenesis, and ovarian function-associated gene expression. miRNA content was assessed by next-generation sequencing and qRT-PCR. Results: Primed AMSC-sEVs displayed a smaller, more uniform size distribution, significantly enhanced particle concentration, and greater negative zeta potential (mean -24.4 mV vs -13.3 mV), suggesting improved colloidal stability. In vitro, primed sEVs dose-dependently enhanced hGC proliferation, restored CTX-induced suppression of AMH, FSHR, and LHCGR, and elevated estradiol and progesterone levels. Apoptotic markers (cleaved Caspase-3, BAX, PARP) were reduced, while BCL-2 was upregulated. Key miRNAs involved in steroidogenic and apoptotic regulation (miR-21, miR-22, miR-23b, miR-145, miR-199a) were enriched in primed sEVs. Conclusion: Primed AMSC-sEVs offer a promising nanotherapeutic strategy to restore ovarian cell function in POI-like conditions via enhanced anti-apoptotic and steroidogenic effects. These findings support the translational potential of Primed sEVs for fertility preservation and the management of menopausal hormone deficiency, including early-stage ovarian insufficiency and genitourinary syndrome of menopause.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.